Thus, HRT is both medically and economically justified in women with severe menopausal symptoms, whereas compliance is an importantjactor in detennining economic benefit in women with less severe symptoms. During long renn therapy the associated beneficial effects on osteoporosis and cardiovascular parameters, and patient moniroring requirements, will assume greater significance.
Treatment Considerations
As women approach the climacteric or have menopause surgically induced. a number of physiological changes occur as a resull of decreased estrogen producti on. Vasomotor instability (hot fl ushes and sweating), mood and sleep disturbances, fatigue, and difficulties with memory and concentration occur in approximately 80% of women. These symptoms may continue for several years, with more than 15% of women still experiencing vasomotor symptoms after 10 years. Dyspareunia and urinary incontinence occur in approximately 40% of women, caused by atrophy of tissues in the urogenital organs due to estrogen deficiency. While there are many alternative treatments available, estrogen-based hormone replacement therapy (HRn is the only option that has proven efficacy in alleviating symptoms as well as in osteoporosis prevenlion.
Efficacy, Benefits and Risks
Oral formulations of HRT undergo subslatltial first-pass metabolism in the liver. This necessitates higher oral dosages compared with non-oral formulations (e.g. transdermal. vaginal, percutaneous, subcutaneous) for equivalent effect and results in a high plasma estrone: estradiol ratio. However. the elevation in plasma estradiol levels induced by therapeutically equivalent dosage regimens results in similar pharmacodynamic effects. Raised levels of fo llicle-stimulating hormone (FSH) and luteinising hormone (LH) are reduced, and vaginal cytology resembles the premenopausal state.
Comparative clinical trials have demonstrated effective relief from menopausal symptoms with oral and transdermal estrogens. Cyclic administration of concomitant progestogens maintained symptom relief, but resulted in periodic bleeding; this was largely ameliorated by continuous regimens. Intravaginal HRT application effectively relieves urogenital symptoms but does not raise plasma estradiol1evels to therapeutic concentrations.
Compliance is a major therapeutic concern with HRT, as prolonged therapy is necessary for most beneficial effects. At present, approximately 10% of postmenopausal women receive HRT. Between 5 and 50% of women withdraw from therapy because of cyclic bleeding episodes, adverse effects, fear of cancer, or lack of effect on symptoms, or on the advice of their doctor.
The predominant adverse effect occurring in women receiving transdermal HRT is local skin irritation. reported in about 14% of patients. Other effects are common to most forms of HRT and include breast tenderness, flushing, headache, fluid retention, nausea and vomiting, irregular bleeding, vaginal discharge and depression. The majority of these symptoms occur in < 2% of patients, and in many cases symptoms may diminish with adjustmenl of the dosage regimen.
Data concerning quality-of-Iife changes with HRT are limited, but most pharmacoeconomic studies have assumed that menopausal symptoms reduce quality of life by a utility factor of 0.05 in patients with severe and 0.01 in those with mild symptoms. More recent clinical data indicate that these utility values may have underestimated the impact of menopausal symptoms on wellbeing. Comparative data concerning quality of life in patients receiving HRT or symptomatic treatment with veralipride for 6 months indicate a clear advantage for HRT.
Phannacoeconomic Considerations
Cost-effectiveness studies have compared the value of several alternative therapies for menopausal symptoms, determined by the efficacy of each regimen in reducing or eliminating symptoms. Conjugated estrogens and transdermal estradiol were both relatively cost effective compared with symptomatic treatments, although deficiencies in study design suggest that confirmation of these results is desirable. Assuming 100% compliance, cost-utility analyses determined that quality-adjusted life year (QALY) changes with HRT were always positive in women experiencing menopausal symptoms, but concluded that costs per QALY were most advantageous in women with severe symptoms or longer therapy duration, and in women who had undergone hysterectomy. Economic benefits of combined eSlrogen and progestogen therapy compared with unopposed estrogen therapy in women with intact uteri differed according to baseline assumptions. Sensitivity analyses indicated that decreasing compliance to 50% after 5 years of therapy reduced annual programme costs, but increased the cost per year of life saved (YLS) from £10 800 to £12 600.
Direct costs du e to menopausal changes have been assessed for urogenital deficiency. Laundry costs for incontinence have been estimated at between 22 and 26 Swedish kronor per day per palient aged 2: 65 years. No data are available for women aged between 50 and 65 years. Costbenefit analysis of estriol treatment of urogenital dysfunction in Swedish women estimated that treatment of all women aged 2: 65 years would result in cost savings compared with treatment of 20% of women. Savings in sanitary materials, laundry costs and treatment for urinary tract infections offset the increased costs for oral and vaginal estriol.
Age-associated disorders are becoming more significant to society as longevity increases. It was estimated in 1981 that nearly 75% of the US population who reached the age of 65 could expect to live for a further decade or more, a 60% increase since 1940. Women outnumber men in the elderly population, and the expected lifespan of women in developed countries is approaching 80 years. Vasomotor disturbances and urogenital deficiency may result from decreased estrogen level s in postmeno-pausal women. In addition, menopause-related physiological changes place women panicularly at risk for osteoporosis; epidemiological patterns of osteoporosis show that mo rbidity and mortality due to osteoporotic fractures are escalating g lobally (Avioli 1988 ).
The consequences of menopause are largely avoidable. Estrogen-based hormone replacement therapy (HRT) is currently the preferred pharmaceutical interventi on; however. there are many issues to be considered before advocating the widespread use of HRT in women experiencing climacteric changes. Risks and benefits of HRT must be assessed, and the attitude and compl iance of both the patie nt and prescribing clinician will affect the outcome. This review evaluates the phannacoeconornic considerations associated with the use of HRT in women experiencing menopausal symptoms. including the outcomes of urogenital estrogen defic iency -that is. the earlier effects of the decline in estrogen levels associated with meno pause. HRT is usually prescribed as treatment rather than as prophylax is for these conditions. A subsequent review in PhannacoEconomics (Whittington & Faulds 1994) will evaluate the pharmacoeconomic considerations associated with HRT prophylaxis for the long term consequences of the decline in estrogen levels. including osteoporosis and changes in cardiovascular risk factors. I
I. Menopausal Estrogen Deficiency
MenQpause is defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity, and can be surgically induced by bilateral oophorectomy. The mean age for naturally occurring menopause is approximate ly 50 years, and the majority of women live one-third or more of their lifespan with the aftermath of climacteric changes in estrogen levels. The primary source of I Because monetary values are dependent upon variable economic climates. COSts should be considered in the contu! of the country and year of cost analysis. However, for broad comparative purposes the uchange rates as of 12 Apri l 1994 are given: SUS = I. SA :0.7208, esc ",0.0057, Pta = 0.0072. SEK '" 0.1271, £ '" 1.4673, '\I: 0.0096. 5 (5) 1994 estrogen in pre meno pausal wome n i s ovarian 17P-estradio l, which can be readil y metaboli sed to estrone or estrio l, both of which are considerably less potent than estradio l. After meno pause the majo r source of estrogen i s estro ne. produced from androstenedio ne in the liver, fatty tissue. skeletal muscle, kidney, brain and hair follicles. Some estrone may be converted to estradiol, resulting in a 0.2 to 0.3 ratio of plasma estradiol to estrone after menopause, compared with a ratio of :<!: I in premenopausal women (Balfour & Hee l 1990) .
Pha rmaco£conomics
The decline in endogenous estrogen production can g ive rise to a number of characteri stic symptoms, including vasomotor instability (hot flu shes and sweating), mood and sleep disturbances, fatigue. and difficulties with memory and concenlration. These affect approximately 80% of women (Miller 1992) . and some symptoms may be interrelated, as vasomotor attacks occurring at night are associated with recurre nt waking periods. The exact mechanism of hot flu shes is unknown . Although these are relatively short-lived. they may begin before menopause and continue for more than a decade after menopause is established. Symptoms may occur in 10 to 45% of premenopausal women, and one study r eported symptoms continuing 15 years after menopause in 18% of women (Lindgren 1993) . In many cases, amelioration of these symptoms is the primary goal of HRT. Women who have undergone hysterectomy (but with intact ovaries) report more severe climacteric symptoms than other women of a similar age, and describe more atypical symptoms including palpitations, irritability, dizziness. depression, muscle and joint pain, shortness of breath and headache (reviewed in Barlow 199 1; Studd et al. 1990 ). The severity o f atypical sy mptoms has also been related to the severity of vasomotor complaints (Oldenhave et al. 1993a,b) .
In general. menopausal sympto ms are assumed not to generate costs per se, even though they have a substantial influence o n quality of life. Although direct costs due to menopause are not readily apparent, Tieffenberg ( 1993a,b) suggested that 22 to 25% of physician vi sits by women in the climac-teric may be avoided by HRT. In addition, there may be indirect costs resulting from decreased productivity, although these would be difficult to detennine. Pharmacoeconomic studies have therefore not included the costs directly associated with menopausal symptoms, but have focused on costbenefit or cost-effectiveness analyses (Botelho 1993; Fujino el al. 1993; Horisberger et al. 1993; Tieffenberg 1993a,b ; see section 5.1). Further research is required to clarify costs associated with menopausal symptoms. Reduced estrogen levels also lead to some atrophy of the urogenital epithelium, which can cause vaginal discomfort, dyspareunia, urinary frequency and urgency, urethriti s, and urinary incontinence (reviewed in Miodrag et al. 1988) . As estrogen levels decline with time, the vaginal epithelium thins and loses its rugae, becoming more prone to trauma. Vaginal lubrication is r educed and the vagina may shorten and become less distensible. Importantly, the urinary bladder and urethra are also sensitive to estrogen. Urethral pressure and length are fundamental in maintaining continence, and both are significantly decreased after menopause. Urethral closure is mediated by the urethral vasculature, musculature and mucosa, as well as the surrounding connective tissue and ligaments, and muscles of the pelvic floor -tissues that are all dependent on estrogen for optimal function (Miodrag et al. 1988) . Typically, urgency and urinary incontinence are greatest 10 years after menopause, and in Sweden an estimated 400 000 women aged;:: 65 years are affected (Brandberg et al. 1991) . The prevalence of SIrCSS incontinence, urgency and frequency ranged between 28 and 63% in 228 women attending a menopause clinic in the UK. but most women had begun menopause :5 6 years prior to the study (Cardozo 1990 ). However, urodynamic measurements were nonnal in 55 to 68% of these women, making initial diagnosis and therefore prevalence levels uncertain. It has been suggested that more than 40% of women aged;:: 65 years have continuous andlor daily discomfort from urinary incontinence and urogenital atrophy (Iosif & Bekassy 1984) . A multicentre trial conducted in Portugal 423 indicated that 35 to 45% of 296 postmenopausal patients (mean age 50.6 years) attending gynaecology clinics reported incontinence as one of their baseline symptoms (Hori sberger el al. 1993 ). At present, approximately 20% of Swedish women with incontinence due to estrogen deficiency are receiving HRT (Brandberg et al. 1991) .
Associated costs of urogenital deficiency syndrome have been estimated in a Swedish study (Brandberg et al. 1991 care, costs of laundry and sanitary materials were assumed to be one-third these estimates.
Treatment Options jor

Menopausal Changes
In general, menopause-related changes that may require treatment can be divided into 4 groups. The prevention and treatment of vasomotor symptoms and urogen ital dysfunction are discussed in this re view, as these changes are considered to be the more immediate consequences of the decline in estrogen levels. Treatment options for osteoporosis, and use of HRT in the long term for prevention of osteoporosis and coronary heart disease are discussed in the subsequent review (Whittington & Faulds 1994) ,
Treatment of Menopausal Symptoms
Frequently, treatment for menopau se-related symptoms is palliative (e.g. sedatives for insomnia, analgesics for headache) or nonexistent. 80% of women who are eligible for HRT either do not seek therapy, have limited access to medical care, or receive inadeq uate counselling from their clinicians (Miller 1992 ; see section 4.2). There are many therapeutic alternatives for vasomotor sy mptoms. including hormonal preparations (e.g. estrogens, progestogens, androgens), no nhormonal agents (e.g. clonidine, veralipride, ergotamine) and lifestyle modifications (e.g. layered clothing, avoidance of caffeine) [Studd et al. 1990] .
Treatment of menopausal symptoms varies worldwide, depending in part on the importance placed upon the need to alleviate the symptoms. In Argentina, 38.5% of women received nonhormonal symptomatic trealment or no treatment for menopausal sy mptoms (Tieffenberg 1993a.b) . A multicentre study in Portugal indicated that 17% of 296 women were prescribed nonhormonal therapy fo r symptom relief. with 40% o f prescriptions being for veralipride (Botelho 1993; Horisberger et al. 1993) .
Veralipride, a neuroleptic dopamine agonist with antigonadotrophic action, is a common treatment for menopausal symptoms i n Europe (LimouzinPharmacoEconomic5 5 (5) 1994 Lamothe et al. 1994) . The acquisition cost of a course of treatment with veralipride in Spain was estimated as Pta 15 133 per patient per year (1989 pesetas). In the same study, annual acquisition costs of transdermal estradiol were Pla23 600 per patient per year. However, comparati ve costs of treatment differed markedly when medical consultations and monitoring costs were included. A 5-year course of veralipride including follow-up cost Pta98 165. compared with Pta362 800 for transdermal estradiol (1989 pesetas). Differences were due to mammography, bone mineral densitometry, and more consultations being required with estradiol therapy (Rovira & Trinxet 1993; see Whittington & Faulds 1994) .
Until recently, even severe menopausal symptoms remained untreated in Japan. Therapy for menopausal symptoms is becoming more prevalent in this country as both physician and patient attitudes change, and a variety of therapeutic options are available. Chinese medicines, sedatives, minor tranquillisers, androgens and autonomic drugs were all listed as possible alternatives to HRT in a recent Japanese stud y (Fujino et al. 1992 (Fujino et al. , 1993 . Fujino and colleagues (1993) examined the effi cacy and acquisi tio n costs of each therapy and found that autonomic drugs and Chinese medicines were least effective, both as monotherapy and in combination. Combination therapy with Chinese medicines and autonomic drugs was also the most expensi ve option at ¥216 per day. Minor tranquillisers and hormonal preparations were found to be the most effective, with tranquillisers priced at ¥50 per day and transdermal estradiol estimated to cost ¥124 per day. However, other than transdennal estradiol, the specific therapeutic agents were not identified, limiting the usefulness of this comparison .
In the US and the UK, HRT is considered to be the treatment of choice for menopausal symptoms, and phannacoeconomic studies based in these countries have limited their therapy comparisons to unopposed estrogen, and combined estrogen and progestogen therapy. Comparative costs of HRT regimens are discussed in section 2.3.
Treatment of Urogenital Dysfunction
Up to 45 % of women may encounter some urogenital dysfunction during the climacteric (section I). Symptomatic relief is commonly prescribed. and a variety of vaginal lubricants are available to ameliorate vag inal dryness and dy spareunia. These include water-based jellies and creams, vegetable oils. yoghurt douches and polycarbophil moisturisers. Studies have indicated that prevention of vaginal atrophy is preferable to tr eatment, and the degree of atrophy is less in women who maintain an active sex life. Preliminary research suggests that tamoxifen may prevent atrophy. but that the effect is dependent on pre-existing estrogen levels (reviewed in Miller 1992). Exercises designed 10 strengthen the pelvic noor are often prescribed for women with stress incontinence. Other treatments include antibiotics for urinary tract infections.
Lillie information is available concerning the econom ic status of treatments for urogenital dysfunction other than HRT. One of the difficulties lies in detennining how much of the dysfunction is due primari ly to the menopause and how much is a natural consequence of the aging process. Brandberg et al. (1991) attempted to address this question in their phannacoeconomic study by assuming that the prevalence distribution of urinary incontinence in women aged 2: 65 years would be skewed towards milder symptoms after treatment with estriol. Thi s implied that estriol treatment could not be expected to effectively treat all fonn s of incontinence in this population. These investi gators estimated that the annual acquisi tion cost of estriol therapy was SEK503 per year for women aged 65 to 74 years, and was SEK372 for women aged 2: 75 years, who received lower dosages. The cost of antibiotics for treating urinary tract infections was assumed to be SEK70 per year (1989 kronor). Unlike other forms of HRT, estriol therapy has limited systemic effects and is therefore more su itable for patients in whom the primary reason for treatment is ur ogenital dysfunction (Kirkengen et al. 
Costs of Honnone Replacement
Therapy (HRT)
Prices of HRT vary (table 0), but in general transdennal products are more expensive than oral fo rmulations, and combination therapy has a higher acquisition cost than unopposed estrogen therapy. Oral conjugated estrogens with or without progestogen have been mosl commonly used to estimate acquisition costs for HRT in pharmacoeconomic studies. although some studies have not identified the proprietary product used and others have used an average price of the different products available ( Whittington & Faulds 1994) .
Comparative pharmacoeconomic data for transdermal and oral HRT preparations are limited. and only 1 multicentre study based in Portu gal has addressed this issue. Horisberger et al. (1993) assessed the comparative acquisition costs and efficacy of transdennal estradiol and conjugated estrogens. both in combination with progestogen therapy, in women with menopausal symptoms. These investigators found that although efficacy was not significantly different between preparations, the price of trans dermal estradiol was 4-fold higher than that of conjugated estrogens. However, if estradiol therapy was administered in a cyclic fas hion (i.e. over21 days. with progestogens gi ven for the following 7 days to complete a 28-day cycle) the difference in costs reduced markedly. Cyclic estradiol therapy cost Esc2804 and Esc3 154 for 3-month low-and high-dose treatment periods, respectively. compared with Esc 1900 and Esc2518 for low-and high-dose conjugated estrogens for 3 months (1993 escudos).
In m ore complex studies. costs of HRT were assumed to include monitoring services in addition to the drug acquisition cost. Daly et al. (1992) assumed that the costs of HRT would i nclude the annual cost of the drugs (£12 for oral estrogen monotherapy and £48 fo r estrogen/progestogen c Estrogen and progestogen constit\len1s are cIeIivefed in the same transdermal patch tor tile $8COOd haH 01 the 28-<Say eycIe.
AbOrBviSriOns: E . estrogen constituent: P ", progestogen constituent; TO " transdermaJ , therapy), 2 extra general practi tioner consultations per year (£6.70 per visit, excl uding prescriptions). plus the cost of an outpatient endometrial biopsy once every 2 years fo r women with intact uteri on estrogen monotherapy (£36.89; 1989/ 1990 UK prices), For 10 years of therapy, treatment costs were £195 for women who had undergone hysterectomy, £336 for unopposed estrogen therapy for women with intact ut eri and £47 1 for combined therapy. Other investigators have included the cost of more extensive mon itoring inc lud ing annual mammography, electrocardiography and bone mineral densitometry every 2 years; one Spanish study estimated the drug acq uisi tion costs plus costs o f monitoring 5 years of transdermal therapy as Pta362 800 in 1989 (Rovira & Trinxet 1993 ).
It appears, therefore, that much of the cost associated with HRT is due to the type and frequency of monitoring and the relative importance placed on monitoring by clinicians . This tends to differ with the various treatme nt strategies in use worldwide; there appears to be little consensus on how best to approach the problem. Section 4.2 discusses the effects that compliance and attitudes of both patients and clinicians may have on treatment costs; for example, many women are reluctant to undergo endometrial biopsy on a regular basis and may decide against HRT for this reason. HRT acquisition costs are moderately higher than those of many other therapeutic options. However, costs must be reviewed in the context of therapeutic effectiveness before the value of the treatment can be assessed appropriately.
Therapeutic Use of HRT
Overview of Phannacology
HRT has been widely prescribed for postmenopausal women for more than 30 years. Conjugated equine estrogens or estradiol preparations were used initially, with the more recent addition of cycl ic progestogens when the risk of endometrial hyperplasia was identified. In addition to 'natural' progesterone, 2 principal types of synthetic progestogen are common ly used with estrogen in clinical practice. The 19-nortestosterone derivatives such as norethisterone acetate, levonorgestrel and Iynestrenol are generall y characterised by the presence of androgenic properties. whereas the l7-hydroxyprogesterone derivatives such as medroxyprogesterone acetate, megestrol acetate and cyproterone acetate have virtually no androgenic activities. Because of structural differences, however, progestogens within both main groups may cover a wide range of biological activities and relative potencies (Jensen 1992) .
There are many comprehensive reviews available that discuss the pharmacological effects of HRT fonnulations (Balfour & Heel 1990; Balfour & McTavish 1992; Corson 1993; Ellerington et al. 1992; Wiseman & McTavish 1994; Youngkin 1990) , and only a brief summary of the main findings related to effects on menopausal symptoms and urogenital estrogen deficiency is presented here.
Pharmacokinetics
Oral HRT preparations usually consist of conjugated equine estrogens, micronised estradiol. piperazine estrone, or ethinyl estradiol as monotherapy or in combination with progestogens. AI-though the efficacy of oral HRT is well establ ished, the high dosages required to compensate for substantial first-pass metabolism in the liver result in a nonphysiological pattern of metabolites. There is also some doubt that different conjugated estrogen products are bioequivalent, as they contain a number of different estrogen ic substances, and the relative proportions of these will determine the metabolic profile of each product (Ansbacher 1993). In general, oral formulations are converted largely to estrone, resulting in elevated levels of both hormones and a plasma estradiol: estrone ratio more typical of the postmenopausal state (0.3 to 0.8).
Non-oral fonns of estrogen delivery include subcutaneous implants, intramuscular depot injections, vaginal creams, pessaries and transdermal delivery systems. In contrast to oral estrogens, non-oral preparations do not stimulate hepatic metabolism and therefore do not elevale plasma levels of renin substrate. Transdermal estradiol increases circulating estrone levels to conceOirations similar to those seen in premenopausal women in the early follicular phase; approximately 40 to 60 ngIL, with a plasma estradiol: estrone ratio of 0.5 10 1.0 (reviewed in Ansbacher 1993; Powers et al. 1985; Selby et al. 1989; Steingold et al. 1991) .
Endogenous and exogenous estrogens circulate in the blood bound to albumin, sex hormone-and cortisol-binding globulins, and cxl-glycoproteins. Free estrogens bind 10 specific estrogen receptors in target tissues, which include the pituitary, breast, li ver, bone, uterus, vagina and urethra. Estrogen metabolism occurs mainly in [he liver, the major metabolites being estrone and estriol and their conjugates, which are considerably less potent than estradiol. Metabolites are mainly excreted as glucuronide and sulphate conj ugates in Ihe urine, although a degree of enterohepatic r ecirculation may occur. Estradiol is rapidly cleared from [he circulation, with a plasma half-life of approximately I hour, and a metabolic clearance rate of between 650 and 900 L/day/m2. With transdennal delivery, maximum plasma estradiol concentrations are achieved within 4 to 8 hours and are linearly proportional to the dosage within a range of 0. Implications of the phannacokinetic profil es of different HRT formu lations on cost effectiveness have not been f ully explored. It is also unknown at present whether the nonphysiological levels of estrone induced by oral conjugated estrogen products affect the efficacy of these form ulatio ns. Resu iling stimu lation o f hepatic metabo li sm may also preclude the use of oral formu lations in women with hepatic impairment. These considerations must be weighed agai nst the higher cost of transdermal products and against the difficulty in controlling dosage with vaginal or percutaneous c r eam ap plications.
1.2 Effects on Sex Hormones and Reproductive Organs
As a consequence of increased plasma estradiol levels induced by HRT, e l evated plasma levels of follicle-stimulating hormone ( FSH) and lute inising hormone (LH) are decreased (table HI) and vaginal cytology is converted to a pattern similar to that found in premenopausal women. Effects on plasma hormone levels were maintained with transdermal estradiol with o r without progestogens in longertenn (2-year) stud ies (Pang et al. 1993) . Age d id not appear to influence the efficacy of treatment (Be l lanto ni e t al. 199 1). • has a greater effect than .
As with other estrogens, unopposed transdermal estradiol has a pro liferative e ffec t o n the e ndo metrium, evidenced b y occurrence of vagina! bleeding and increased incidence of proliferative endometrium found on biopsy (Clisharn et a!. 1992; Haas et aL 1 988), Changes in uteru s size may depend o n the time of commencement of HRT. A minima!, nonsignificant increase in uterus size was observed i n women who began HRT 2 to 10 years afrer menopause compared with un treated women, whereas uterine size was sig nificantl y g r eate r in women who had st arted HRT before menopause. However, the mean uteri ne artery pulsatility index was lower in treated women compared with untreated wome n, i ndicating decreased vascu lar re-sistance and possibly an increase in uterine blood fl ow (Pirhonen et al. 1993) .
Progestogen in combination with estrogen therapy appears to prevent the development of hyperplasia, while inducing adequate secretory changes in the endometrium. Because of the possibility of progestogens adversely affecting the serum lipid profile, the lowest dosage that prevents hyperplasia is currently r ecommended . A recent report suggested, however, that combined estrogen and progestogen use actually improved the lipid profile compared with estrogen monotherapy (Nabu lsi et al. 1993) . Other studies have shown that micronised estradiol 1 .5mg daily for 24 days combined with desogestrel 0. 15mg daily for 12 days was sufficient to prevent hyperplasia while improving serum lipid profi les (Saure et a1. 1993; Whittington & Faulds 1994) . However, transdermal estradiol 0.05 mg/day combined with transdermal norethisterone acetate 0. 15 mg/day was considered inadequate in inducing endometrial changes (Fraser et aL 1993) .
Preliminary resu lts with subcutaneous estradiol implants indicate that endometrial changes are similar to those evinced by transdermal and oral delivery systems (Rees et al. 199 1; Suhonen el al. 1993 ).
Therapeutic Efficacy in Menopausal Symptoms Including Urogenital Dysfunction
Interpretation of the efficacy of HRT is complicated by the number of different products and formulations available, and by the lack of agreement concern ing effective dosages. In addition, prescribing behaviour has changed over the years; previou sly 2.5mg conjugated estrogens was the usual daily dosage, whereas at present 0.625mg dai ly is more commonly prescribed. Min imum daily dosages of estrogen that prevent bone loss are ass umed to be conjugated equ ine estrogens 0.62Smg. ethinyl estradiol O.02mg. estrone sulfate 0.62Smg (Genant et al. 1989) , transdermal estradiol 0.05mg (Balfour & McTavish 1992) ; and subcutaneous estradiol implant SOmg: these dosages are also sufficient to relieve mild to moderate menopausal symptoms (Baber 1993) .
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Comparative studies of transdermal and oral estrogen preparations have indicated similar effectiveness in re lief of menopausal symptoms (Melchert 1988; Nachtigall & Vtian 1988; Tamadaet al. 1992b; Zichella et al. 1 988) . Conjugated equine estrogens 0.625mgdai ly in combination with medroxyprogesterone acetate, levonorgestrel or norethiterone alleviated menopausal and urogenital symptoms in I-year dose-comparison stud ies (luciano etal. 1993; MacLennanet al. 1992 MacLennanet al. ,1993 Weinstein et al. 1 990) . Maclennan et aL (1992) reported a 62% reduction in symptom score after 6 months of therapy; other investigators reported improvement in symptom s in all patients (luciano et al. 1993; Weinstein et al. 1990 ). Cyclic administration of progestogens with either conj ugated estrogens or estradiol resulted in menstrual bl eeding, which was largely prevented by conti nuou s regimens (Clisham et aL 1991 ; Keller et al. 1992 : Luciano et al. 1993 Maclennan et al . 1 992, 1993 : Ross et al. 1993 . lWo-and 3-year studies wi th estradiol plus norgestrel or norethi sterone acetate confirmed these find ings (Obel et aI . 1993; Plunkett & Wolfe 1 992).
The effects of estradiol on climacteric symptoms may be dose dependent. Adouble-blind, pl acebocontrolled dose-finding study oftransdermal estradiol indicated that sign ificant differences from placebo were observed with estradiol 0.025mg but not 0.012mg daily (Tamada et al. 1992a ). However, it appears thai reduced progestogen dosages plus estrogen mai ntai n symptom relief. Menopausa l symptoms were relieved and serum lipid profile improved in postmenopau sal women receiving oral conjugated estrogen 0.625mg with either 2.5 or Smg medroxyprogesterone continuously for I year (Weinstein et al. 1990 ). Oral piperazine estrone O.7Smg daily combined with noreth isterone 0.35mg daily in 3-day phases (alternating with progestogen-free 3-day phases) prevented nushing in > 7S% of women, with a small but statistically significant decrease in high density lipoprotein-choleslerol (HDL) and triglycerides observed after 2 years of therapy ( Casper & Chapdelai ne 1993).
Other formulations have demonSITaled similar effectiveness in relieving symptoms. Percutaneous estradio l gel alleviated menopausal sy mpto ms in a 3-month , randomised, placebo-controlled trial (Kom afel & March 1992) . Subcutaneous estradiol 25mg implan ts provided symptom relief for between 28 and 35 weeks in 12 postmenopausal women (Owen el a!. 1992) .
Intravaginal application of estriol cream significantly reduced the incidence of urinary tract infection in postmenopausal women in 2 placebo-controlled trials ( Ki rkengen et al. 1990; Raz & Stamm 1993) , A meta-analysis of clinical trials that used oral and vaginal estriol , estradiol . conjugated estrogens, piperazine estrone sulphate and quinestradol to treat urinary incontinence in postmenopausal women found an overall significant effect on both clinically confinned stress incontinence and subjective improvement of incontinence symptoms (Fantl et al. 1994 ). Estradiol-releasing silicone vagina l rings provided urogen ital sy mptom improvement fo r a minimum of 90 days in 222 postmenopausa l women (S mith et a l. 1993). Typically, vaginal appli cations of HRT a re des igned for local effect only, and the refore dosages of estrogen admin istered by these devices are low; for example. si licone vagina l rings released 5 to 10J.1g over a 24-hour period, which was insufficient to raise plasma estro ne or estrad iol levels above postmenopausal levels (S mithetaI. 1993) .
Phannacoeconomic studies based in the US have not stated efficacy rates for relief of menopausal symptoms; most appear to have assumed complete re lief with treatment (Tosteson 1993 : Weinstein 1980 Weinstein & Schiff 1983) . However. Brandberg et al. ( 1991) assumed that the prevalence of urinary tract infection would decline with estriol therapy according to data from a study in 70·year-old women. More recen t economic evaluations in Portugal, Argentina and Japan have used prospective data obtained during the study (Fujino et al. 1993; Ho risberger et al. 1993 : Tieffenberg 1993a .b).
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Tolerability
In general, a dverse reactions can be subdivided into systemic effects, which tend to occur with all HRT therapies that raise plasma estrogen levels, and local effects. which primarily depend on the method of de li very. Ris ks associated with long tenn therapy are evaluated in the accompanying review (Whittington & Faulds 1994) and are only briefly mentioned here.
Local adverse reactions with transdennal applications a ppear to be more frequently reported than systemic effects. The most common reason for discontinuing transdermal estradiol treatment appears to be local skin reaction to the transdennal d eli very system. The reponed incidence of dennatological adverse events in large clinical trials (> 100 pa· tients) of8 to 52 weeks' duration, ranged from 5 to 35% (mean 14%) [reviewed in Balfour & McTavish 1992; Cheang et al. 1993; table IV] . The most commonly reported reactions consisted of mild erythema and itching al the site of applicat ion, which resolved withi n 1 1 02 days o f r em oving the syste m. Severe cutaneous reactions (severe itching/erythema a nd/or pustules) leading to discontinuation of treatment occurred in a minori ty (6.3%) of patients. Cutaneous reactions to the transdermal deli very system may occur more frequently in humid tropical conditions than in temperate climates, because of increased cutaneous occlusion (McCarthy et al. 1992) . Adhesiveness may differ between types of transdermal formul ation, which may be a further consideration (Transdermal HRT Investigators Group 1993; Van Leusden et al. 1 993) .
Other adverse effects of HRT arc typical dosere lated estrogenic effects, such as breast t enderness. vaginal spotting o r bl eeding. fluid retention, headaches and nausea occurring in $ 2% of patients (table IV) . Progestogen use may be associ· ated with gastrointestinal disturbances. irregu lar menses, weight gain, headaches and depression. In many instances, dosage adj ustment can e li mi nate these adverse experiences. Rarely, asthmatic bronchoconstriction may be exacerbated by estrogen therapy (Collins & Pe iris \993). Although most pharmacoeconomic evaluations have included assumptions concerning the risk of breast or endometrial cancer (see Whittington & Faulds 1994) , local or systemic adverse effects have been considered less often. Some investigators have calcu lated the economic effect of bleeding induced by progestogens by including the costs of dilalation and curenage (Daly et al. 1992; Weinstein 1980; Weinstein & Schiff 1983) or have assumed a decrement in quality of life and calculated the adverse effect in quality-adjusted life years (QALYs) [Cheung & Wren 1992; Tosteson et al. 1990; Weinstein & Schiff 1983] . For example, cost per QALY for symptomatic women with in tact uteri receiving estrogen and progestogens was calculated as $A34 700 for 5 years' therapy assuming progestogen adverse effects, and as $A 17 600 without adverse effects (1988 Australian dollars). Differences in costs due to adverse effects of progestogens were less extreme in other studies; for 10 years of HRT, added costs per year-of-life saved (YLS) for di latation and curettage were £14 200 for a relative risk of 1.0. compared with £ 14 900 for a relative risk of 2.0 (198911990 pounds sterling) [Daly et al. 1992] . It is uncertain from these reports whether the investigators used the same parameters for determining adverse effects of progestogen (for example, whether regular withdrawal bleeding as well as irregular bleeding was included as an adverse effect), and therefore meaningful comparisons are untenable.
Vaginal bleeding occurs in approximately 50 to 60% of postmenopausal women during the firs t year of estrogen plus progestogen therapy (Barentsen et al. 1993; Hahn 1989) . Daly et al. (1992) assumed that women receiving unopposed estrogen therapy have a relative risk of 2.0 for hysterectomy or dilatation and curettage. and in women receiving combined estrogen and progestogen therapy the relative risk was assumed to be 1.25. The increased risk was assumed to last for the duration of therapy, at which poi nt the risk reverted to that within the untreated population.
The risks and benefits of HRT are important considerations from many perspectives. For society as a whole, the risks and benefits of HRT play a major role in determining the final cost effectiveness of this therapy and, in some countries, which patient groups are considered eligible for therapy. For the individual patient receiving HRT, benefits of symptom relief from hot flushes, urogenital deficiency syndrome and prophylaxis against osteoporotic fraclUre and cardiovascular disease need to be we ighed against the inconven ience of prolonged menstruation and the risks of endometrial cancer, gallbladder disease and possible breast cancer. These issues are discussed in depth in Part U of this review (Whiltinglon & Faulds 1994). The prescribing clinician has the added concerns of compliance, c ho i ce of therapy, and the effectiveness of screening procedures. Further considerations are the influence that prior hysterectomy, surgical versus normal menopause, and opposed versus unopposed estrogen replacement therapy may have on the magnitude of the associated risks and benefits.
Quality-oj-Life Considerations
Several factors influence patient quality of life, and therefore affect cost-util ity outcomes with HRT. In addition. quality-of· li fe issues have a substantial influence o n tolerability and acceptability of the therapy, and the subsequent effect on compliance may also affe ct economic OUicomes.
1 Menopausal Symptoms
The degree to which menopausal symptoms alter quality of li fe remains to be detennined. Early studi es used hypothetical values that were not based o n ac tual data (Weinstein 1980; Weinstein & Schiff 1983) . but that were subsequently e mployed in later analyses as s tandard assumptions (Cheung & Wren 1992; Daly et al. 1992; Weinstein & Tosteson 1990) . More recently. a V K s tudy measured the impact of me nopausal symptoms on quality of life, using time trade-off techn iques and a r ating scale, and found that both measures were consistent but poorly related. Time trade-off results yielded utility measures of 0.85 fo r patients with mild and 0.64 for those with severe menopausal sy mpto ms, whereas the rating scale yielded utility scores of 0.65 and 0.30, respectively (Daly et a1. 1993 Although it is accepted that HRT may improve qua lity of life by amelio rating phys ical symptoms, there is substa ntial controversy concerning alleviation of psychological symptoms of menopa use wi th HRT. An inc idence of psyc ho logical patho logy of 52% in gy naecology c linics. and 20% in general outpatien t clinics, related to menopausa l estrogen deficiency has been reported (Studd et al. 1990 ). These issues have been comprehensively rev iewed (Bac hmann 1993; Gath & lies 1990; Hunter 1990; Utian 1989) , and it appears that the main difficulty in reaching consensus ste ms from the l ack of objective definitions for qual ity of life. In addition, c hanges in well-be ing that may occur at menopause are strong ly influe nced by social and c ultural milieu; a woman who e me rges from purdah at menopause with public vene rati on is likely 10 view me nopau se quite differen tly from a w o man who belongs to a cu lture that glori fies youthful beauty.
Many investigators ha ve suggested a moodelevating ' mental ton ic' effect caused by HRT (reviewed in Hunte r 1990; Vt ia n 1989). Effo rts have been made to q ua ntify these changes with a variety of meas ureme nt tools. including standardised quest io nnai res (e.g. Nottingham Health Profile, Psychological General Well-Being Index, and the Women's Hea lth Questio nnaire) and subjective rating of menopausa l sy mpto ms with visual analogue scales and diaries. A series of studies have shown that significant improvements in quality-of-life parameters are feasi ble with HRT (Daly et al . 1993 ; Limouzin-Lamothe e t al. 1 994; Tomoda et al. 1992; Wi klund el al. 1992a Wi klund el al. .b. 1993 . One double-blind, placebo-controlled study in symptomatic postmenopausal women showed that quality oflife improved in both treated and control groups, but thatlhe improvement was significantly greater in the treatment gro up. Patients received transdermal estradiol or placebo for a 3-mo nth period, and. in addition to amelioration of climacteric symptoms, patients noted improvement in well-being and health-related quality of life (Wiklund et al. 1993) .
Outcomes in a non blinded study in 55 Japanese women concurred with these results and indicated that transdermal estradiol had an added advantage in symptom improvement compared with Chinese medicines, minor tranquillisers, autonomic drugs and sedati ves (Fujino et a l. 1992 (Fujino et a l. , 1993 . This study used a paired comparison of symptoms and the Kupperman index of ranking to determine the weighted importance of each symptom to the patient.
Another open, comparative trial i n 500 French women indicated that HRT was superior to symptomatic treatment with veralipride in almost all assessments of quaJity of life (Limouzin-Lamothe et al. 1994) . A globaJ questionnaire (the MenopausaJ Global Health Status Indicator) was constructed from 5 sources: the Women 's HeaJth Questionnaire, the Psychological General Well-Being Index, a sleep problems questionnaire, the Sexual Behaviour Questionnaire and questio ns o n social as pects of life. Patients were randomised to receive e ither transdermaJ estradiol 0.025 to 0.1 mg/day daily plus oral chlormadinone acetate 10 mg/day for 12 days per month, or veralipride 100 mg/day for 20 days per m onth. Clinical effectiveness and tolerability monitored by the physician at the end of 6 months' treatment was significantly better with HRT than with veralipride . All patients in the HRT g roup received estradiol plus progestogen regardless of uterine status, and the investigators noted that the addition of the progestogen did not appear to interfere with the improvement in quality of life caused by estradiol . Subjective quality of life improved in both g roups, but was significantly greater with HRT than with veralipride except in scores for ' household' jobs and ' professional' life subscales of the social questionnaire (Limouzin-Lamothe et al. 1994) .
In a UK study using the time trade-off method. women receiving HRT who rated themselves as previously having severe menopausal symptoms were willing to t rade off more time for quality of life than were all women who had never used HRT (Daly e t al. 1993 ).
It can be argued that the changes in quality of life with HRT reflect the relief of physica l symptoms o nly; for example, hot flushes and night sweats arc likely to cause sleep disturbances, and therefore mood changes. Placebo may also induce improvements, which indicates the difficulty in directly attributing c hanges in quality of life to HRT. In particular, self-rated improvements in memory, while a u seful corollary to well-being, require substantiation with more quantitati ve testing methods. A randomised, double-blind, placebo-controlled study in asymptomatic postmenopausal women attempted to address these issues. 36 women received oral conjugated estrogen O. 625mg or 1.25mg or placebo, and were monitored at 3-weekly intervals. Results indicated a sig nificant improvement in income management in the Profile of Adaptation to Life questionnaire, and on the Beck D epression Inventory within 3 months of starting active treatment. No significant changes were observed in the Minnesota Multiphasic Personality Inventory-I 38 domains, nor within memory assessments by the Wechsler Adult Intelligence Scales (Ditkoff et al. 199 1). Phillips and Sherwin (1992) assessed the effects of HRT on mood and memory function in women with surgically induced menopause and correlated the results with plasma estradiol levels. This double-blind, placebo-controlled study in 19 wo men indicated that there were no s i gnificant differences in the anxiety, depression or hostility subscaJes of the Multiple Affect Adjective Check List in either treated or control groups, but a s ignifica nt decrease in immediate and delayed recall of paired associates was no ted in the placebo group. In addition, an increase in the immediate recall of paragraphs was observed in women after 2 months of estradiol treatment, which coincided with increased plasma estradiol levels. The quality-of-life alterations due to urogenital estrogen deficiency, and the effects of urethritis and urinary incontinence, have not yet been determined.
Compliance Wi th and Altitudes
Toward HRT
HRT is a long term therapy: for full protecti ve effect it appears thai women must remain o n therapy for 10 o r m o re years, commencing al menopause and conti nuing for most of the remainder of their lifespan. Therefore. the attitudes of both patients and prescribing clinicians are very important in maintaining compliance. Attitudes towards compliance with HRT for prevention of osteoporosis and the long term risks of therapy are discussed by Whittington and Faulds (1994) [Part Ill .
The proportion of postmenopausal women receiving HRT for prevention of osteoporosis is currently low. In 1987, on ly 1 0% of 40 million postmenopausal women in the US were receiving HRT. A si ngle-ce ntre UK study reported that 80% of patients received HRT primarily for menopausal symptoms. whereas 6% were using HRT as prophylax is against osteoporosis ( Roberts 1991 ) . Although 58% of 1500 women in a Scottish s urvey agreed that symptomatic menopausal women should receive HRT, only 16% of women had ever taken it. and 9% were currently receiving therapy (S inclair et al. 1993 ). An unpublished fi eld study of 2500 women aged between 45to 55 years, revealed that although 70% of women had been prescribed HRT, 30% had never filled the prescription and 10% took the medication sporadically (reviewed in Nachtigall et al. 1990 ). The majority o f women are prescribed HRT for amelioration of menopausal symptoms rather than for prevention of osteoporosis.
Women may refuse treatment because of unwanted bleeding. 38% of women with low bone density in a UK study refused HRT because of the return of the menstrual cycle (reviewed by Clement 1994) . Other reports suggest that unwanted bleeding is the most common reason for discontinuation of therapy (Lindgren 1993 ).
It appears that attitudes toward HRT may be directly correlated with the level of information about this therapy. A large Norwegian survey of randomly selected women ind icated that most information was obtained from women's magazines, and that women who had obtained information from a doc-
tor felt more positive IOward HRT than those who had not (Hunskaar & Backe 1992) . Similarly, studies in the UK indicated that British women were also more likely to obtain information through media sources (Garton et al. 1993; Kadri 199 1; Roberts 1991) . Reports from the Swiss Drug information Centre suggest that doctors may not adequately address questions from their patients regarding HRT (Fritz 1993) . Furthermore, 24% of perimenopausal women surveyed in the UK felt they had to apply pressure on their general practitioner to obl3i n HRT (Kadri 199 1) . Studies in Finland and the US have shown that gynaecologists are most likely to prescribe HRT, and they are more favourably di sposed toward long term therapy than are other clinicians (Greendale et al. 1990; Hemminki et al. 1993) .
Compliance has been shown to decrease significantly with the duration of therapy ; one clinical practice reponed that of 114 women prescribed HRT, 96 were continuing therapy after I year (Coope & Roberts 1990) . A Swed ish study involving> 1800 women showed that although vasomotor sy mptoms affected 51 % of women. only 10% of women were currently receiving HRT. A further 10% of women had previously used HRT bu t had ceased therapy on the advice of thei r doctor or because of no symptoms. no effect on symptoms, adverse effect s or fear of adverse effects. Of those women who ceased treatment. 49 % slopped within the first year of therapy. and 70% were still experiencing vasomotor symptoms after therapy withdrawal ). An Australian study confirmed that onl y 73% of women continued to take HRT I year after commencement of therapy (Wren & Brown 199 1) . Nachtigall (1990) s uggested that compli ance could be improved by patient education, including written material for the patient to take away, and by avoiding unnecessary endometrial biopsies. In single centre and muiticentre surveys, only 7 and 5% ofpatients, respectively. had discontinued therapy beyond I year after receiving information. However. 17% of patients withdrew from therapy within I year in an Australian study, despi te r eceiving an initial I-hour consultation and individualised therapeutic regimens, together with a l6-page explanatory booklet (Wren & Brown 1991) .
In pharmacoeconomic analyses to date, there is little agreement on the level s of compliance to be expected from the general population of postmenopausal women. Some investigators have discussed HRT in terms of the number of women prescribed therapy currently and in the (hypothetical) future; these studies assumed 100% compliance (and therefore full efficacy of therapy) in all women who received a prescription (Brandberg et aI. 1991 : Daly et al. 1992 . In additional sensitivity analyses. the duration of treatment, the degree of fracture ri sk, and the likelihood of abandoning treatment have been examined (see also Whittington & Faulds 19(4) . Daly et al. ( 1992) examined scenarios where compliance reduced over time. They assumed that compliance with unopposed estrogen would be 100% for the first 5 years. fal ling to 50% thereafter: compliance with combined estrogen and progestogen was assumed to begin at 67% and reduce to 33% after 5 years of therapy. Using a popu lation of 279000 women receiving therapy for 10 years (the mid-year [1988] 50-year-old female popu lation of England and Wales), they calculated that the decrease in compliance reduced the annual steadystate programme costs from £ 121 million to £66 million (1 988 pounds s t erling) but increased the cost per year of life saved (YLS) from £10 800 to £12600. In thi s scenario, 18% of women received estrogen replacement therapy and 82% received combined estrogen and progestogen therapy, and the cardioprotective effect of estrogen was assumed to be halved with combined therapy. In contrast, Rovira and Trinxet (1993) used a computer simulation that progressive ly decreased comp liance over each year of treatment, presuming al l women receiving HRT had abandoned treatment after 10 years. In addition, they performed sensitivity analyses for 20, 60 and 80% compliance at the end of 10 years of therapy. Details of the results were unavailable, but it appeared that as compliance decreased, so did cost, with maximum cost effectiveness achieved after 5 years of therapy.
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Other in vestigalOrs have used prospective data in pharmacoeconomic analyses to determine the probability of abandoning treatment based on the Kupperman index and the satisfaction with treatment expressed by women within the study. From this, the probability of gain (improvement with treatment) was compared between hormonal and nonhormonal treatment, and costs (1991 US dollars) and years-of-Iife saved (YLS) were weighted accordingly. With these weightings it was estimated that nonhormonal treatment would result in 40.3% of the target popu lation being effectively treated at a cost of $US44 708 per YLS, compared with 75.7% of the target population effectively treated with transdermal HRT at a cost of $US3 1 625 per YLS (Tieffenberg 1993a,b) .
Pharmacoeconomic Appraisal 0/ HR T
In general , pharmacoeconomic studies are undertaken to assist decision-making in a specific context, and the methodology is adapted to suit the question to be answered by the study. For example, in the analysis of short term benefits due to the possible resolution of menopausal symptoms and the immediate prevention of urogenital atrophy, costs are applied over a short time period and cost discounti ng is less critical than for analyses conducted over the longer term (Freund & Dittus 1 992) . In this way the cost-benefit philosophy is applied to the study itself. to minimise wastage of research resources. Thi s approach, however, then leads to problems when the attempts are made to apply the study findings to a different country or situation, as study conclusions are often highly dependent on the original set of assumptions.
The ideal pharmacoeconomic appraisal of HRT in menopausal women would assess the innuence of all the risks and benefits; consider the effectiveness of different treatment regimens for all types and degrees of menopausal symptoms, urogenilal deficiency and osteoporotic fracture; evaluate the effect of different compliance levels over treatment durations: and adjust the outcomes with respect to the health status and age of women in the popu lation. quality-of-life determinants, direct and indi-rect costs of different treatment options for each outcome, cost-discounting and mortality rates. Ie would also include sensitivity analyses to help determine the cost elements that have the most effect on the outcome o f the study. This then permits assessment of the effect of altering variables within the study to apply the data to different scenarios (Freund & Dittus 1992) . With little agreement in the literature concerning the optimum duration of trealment, l evels of compliance and quality-or-life effects of HRT, and the lack of information available on many important factors. Ihis task is clearly not possible at presen!. Publi shed studies have taken a number of approaches to address these problems and have used various assumptions about the comparative importance of risks and benefits. Thus, resul ts are difficult to compare directly between studies and must be appraised in the context of the different methodologies used.
1 Treatment of Menopausal Symptoms
J. J Cost-Benefit Appraisal
Cost-benefit analyses of HRT should compare the costs of illness andlor alternative treat ment of menopausal sym ptoms with the monetary value of the benefits (e.g. savings in other treatments, decreases in ischaemic heart disease, increases in productivity) minus the costs associated with HRT (e.g. drug acq uisition costs, endometrial biopsy, medical consultations). The final oUlcome of costbenefit analysis is expressed as a monetary value (Freund & Dittus 1992) . Pharmacoeconomic studies of HRT to date have not concentrated on this issue: typically, the cost-benefit data are peripheral to the main focus of the study. Nevertheless, some limited conclusions are possible.
Willingness to pay is a measure of the benefit to be gained by one therapy compared with another. Tieffenberg (l993a, b) used this method to determine the relative cost benefit of transdermal HRT compared with other hormonal and nonhormonal therapies used for menopausal symptom s in Argenti nean women. A total of 58 women were surveyed 5 months after the conclusion of a prospec-
tive comparative trial of these therapies. 38% of women were still receiving transdermal HRT, 41 % were receiving no treatment and 16% were receiving nonhormonal therapy. Approximately 75% of women were willing to pay the market price for trans dermal HRT, and almost 50% of women were willing to pay twice the market price (i.e. about SUS40 per month) for transdennal HRT, r egardless of the t ype of therapy they were currently receiving. Health insurance coverage had a sign ifican t influence on these results: women with coverage were more willing 10 pay for treatment Interestingly, the majority of women fa voured some form of treatment, even though 32.5% abandoned transdermal therapy because of unwanted adverse effects (23.2%) or because of fear of cancer (9.3%).
Cost-Effectiveness Appraisal
Cost-effectiveness studies are typically of value in determin ing t he mosl economic regimen after the deci sion 10 Ireat has been made. The cost effec tiveness of HRT fo r treatment of menopausal symptoms has been briefly considered in 2 preliminary prospective studies . H orisberger el al. (1993) examined the effectiveness of various treatments for menopausal symptoms, including vera1i pride, and transdermal estradiol or conjugated estrogens, as monolherapy or combined with medroxyprogeslerone ace late, norethisterone, promegestone or prox ibarbal (a barbiturate). A 10lal of 296 women with sponlaneousor surgically induced menopause were r ecruiled from 12 i nslitulions in 3 P ortuguese ci lies; the more common ly prescri bed regi mens were then cOSled and compared for effectiveness in relieving symptoms. 1\vo measures were used. the cost per reduced occurrence, and the cost per reduced severity. After I and 3 months of therapy. palients reponed how many of 21 symptoms had disappeared and the level of severity of the 4 main symptoms, which were identified as sweating, hot flushes, insomnia and paraesthesia. Horisberger et al. ( 1 993) found oral conjugated estrogens 0.625mg daily 10 be the most and veralipride 10 be the least cost-effective therapy in both the r eduction of severity and the eradication of symptoms (table V) . This study did not use establ ished methods in assessing symptoms and did not include adverse effects of Irealment, risks or benefits, nor any cOSls other than drug acquisition costs based on the retail price in Ponugal in Apri l 1993. Therefore, the outcome gives only an approximation of cost effectiveness of the various regimens.
In a similar study conducted in Japan, Fujino et al. (1992 Fujino et al. ( , 1993 used the Kupperman index and paired comparisons 10 weight menopausal symptoms according to their effect on quality of life. Using the qualily-of-life index thus generated, they assessed various treatments to detennine their effect on symptom improvement after 3 weeks of treatment. Assessments were made I week after the withdrawal of therapy. These investigators examined the efficacy of each tTemment in relation to acquisition costs and observed that hormone preparations and minor tranquillisers were the most cost effective in reducing symptoms (cost per day ¥31.7 and ¥49.9, respectively; year of cost analysis not stated), and Chinese medicines either as monotherapy or in combination with autonomic drugs were Ihe least cost effective (cost per day ¥213.0 and ¥215.9, respectively). The type and fonnu lation of the drug regimens were not outlined in the study, and no adverse effects or other risks, benefits or costs were included, which limits interstudy comparisons. Notwithstanding these limitations, in both the Japanese and Ponuguese studies, transdermal estradiol was the second most cost-effective option, despite a relatively high acquisition cost. As these studies included only acquisition costs in their analyses and the majority of costs associated with HRT appear to be due to monitoring costs (section 2.3), it seems possible thai the OUlcome would be very different if monitoring costs had been included. In Portugal, the use of transdermal HRT reduced the number of visits to the gynaecologist, and thus avoided fees for 1.5 to 2.5 consultations per patient. Savings in consultation costs offset the price differences between transdermal systems and the lower priced oral HRT (personal communication, Dr Horisberger).
J.3 Cost-Utility Appraisal
In cost-utility studies, a value is placed on the change in quality of life resu lting from the alleviation of symptoms. [n most studies, symptomatic improvement induced by HRT was assumed to add 0.01 QALY for each year of (Temment. The final cost of a QALY was then calculated from all the costs of treatment and the assumed savings due to benefits. The COSI ulilily of trealing menopausal symptoms has been considered in Australian, UK and US settings. Constant rate cost-discounting levels of either 5% (Cheung & Wren 1992; Weinstein PhannacoEconomic$ 5 (5) 1994 myocardial infarction. With no cardiovascular benefil assumed. 5 years of unopposed estrogen therapy gave a QALY change of 0.037 in women with intact uteri . compared with a QALY change of 0.022 in women receiving combined therapy. 15 years of treatment increased the QALY change 100.088 and 0.072. respectively (table VI) . Assuming a re lat ive risk of 0.5 for death from myocardial infarction, 5 years of treatme nt gave a l ifetime QALY gain of 0.034 for combined therapy and 0.048 for unopposed estrogen therapy, compared with 0. 11 3 and 0.1 30. respectively, for 15 years of treatment. Costs per QALY appeared to be directly re l ated to risk rates for myocardial infarction regardless of the type of therapy ( fig . I) .
Wein stein and Schiff ( 1983) approached this subject from another perspective and determined the minimum utility value assigned to sympto m re lief that would result in positive health benefit with unopposed estrogen therapy. The value of sympto m relief requ ired was> O.OCI7 QALYs per year of therapy. Outcomes varied with the duration of therapy: 5. 10 and 1 5 years of treatment yielded net QALY gains of 0.006. om and 0.071 , r espective ly. Examin ing the effect of progestogen in combinatio n with estrogen r evealed that combination therapy was high ly cost effective, panicularl y if endometrial biopsies were omitted, if therapy continued for ;::: 10 years, and if quality of li fe was unchanged by periodic bleeding. Under these conditions, cost per QALY was $U$5600 (in J 982 US dollars) for 15 years of treatment.
All studies indicated that costs per QALY were most advantageous with severe symptoms, with longer therapy duratio n. and in women who had undergone hysterectomy. Economic benefits of combined estrogen and progestogen therapy compared with uno pposed estrogen therapy in women with intact uteri differed according to baseline assumptions. However, all studies assumed 100% compli ance during treatment; an overestimatio n of the cost utility is therefore likely if levels of compliance follow those r eported in clinical trials (section 4.2) . In add ition. studies only compared o ne type of HRT with another; no information i s available . . , 0.Il22' SA23900 , Auumes no actverse raactions !Of progestogen therapy.
, Auumes baseline assumptjons of risk as outlined in Whittillglon and Faulds (1994) .
• values are no! disoounted .
Values are giverllOf no inerea5ed risk 01 breast cancer. end an inerea5ed risk of SO'Yo, respectively.
Abbreviations: E" unopposed estl'Ogl'lrl lherapy; E + P . combined eslrogoo and progestogen therapy; NS . not stated ; y" year. concerning (he cost utility of nonhormonal treatment for menopausal symptoms.
Treatment of Urogenital Dysfunction
Cost-Benefit Appraisal
To date, only one study has focused on the savings possible by treating urinary incontinence with HRT. Brandberg et al. (1991) addressed this question from a societal perspective in a Swedish setting. They compared the costs and savings of treating either 20% or 100% of incontinent women aged ~ 65 years with estriol and found that the savings incurred by decreased laundry and sanitary material costs, and decreased costs for treatment of urinary tract infections, more than offset the cost of estriol I or 2 mg/day or vaginal estriol 2 applications/week. Total costs were SEK992.8 million for treating I(}()% of women compared with SEKI300 million for treating 20% of women, an estimated saving of 23% (table VII) .
These investigators assumed that the population of Swedish women aged ~ 65 years remained static and used a prevalence approach to detennine direct costs incurred per year based on 1987 figures. 20% of women were assumed to be receiving treatment at the outset of the study. Costs due to adverse effects and screening procedures and indirect costs were not included; nor were other risks and benefits of HRT considered. Brandberg et al. (1991) also detennined which payers would benefit from the alterations in cost structure resulting from treatment of all incontinent women aged ~ 65 years, compared with 20% of women receiving treatment ( fig. 2 ). Three groups were identified: the patients themselves, who pay a maximum of SEK60 for a prescription and SEK60 for a medical consultation; the county councils and municipalities, which pay for all geriatric care and a proportion of the home-care assistance; and the National Social Insurance Board, which shares laundry costs and costs of sanitary materials with patients. Patients and the county councils were estimated to gain SEK74 and SEKI53 million. respectively; although the National Social Insurance Board pays more for pharmaceutical agents and physician visits, net savings due to decreased treat· ment for urinary tract infections and lower consumption of sanitary material are estimated to be SEK58 million (1989 kronor).
Other investigators have included urogenital problems in analyses of the economic impact of menopausal symptoms. but have considered these of less importance than vasomotor or psychological symptoms (Fujino et al. 1993; Horisberger et al. 1993) . No direct cost-effectiveness or costutility data are available for HRT in the treatment of urogenital dysfunction.
6, Pharmacoeconomic Status of HRT
The decision to recommend HRT must be based on the benefits and risks to the patient, and on the costs and benefits to society as a whole. Costs of disease in the elderly will escalate with increasing longevity, and health interventions that prevent disease at reasonable cost will become increasingly important. The loss of well-being that accompanies menopausal changes in women is largely preventable by a number of acceptable treatment strategies; the key concern then becomes one of cost effectiveness. Comparative pharmacoeconomic data in the treatment of menopause-related changes are also limited, so that treatment strategies other than HRT are difficult to assess in context. Thus, many of the following conclusions require further supporting evidence.
General Prescribing Considerations
HRT is the therapy of choice in many countries for alleviation of menopausal symptoms and prevention of osteoporosis, and current clinical data endorse this conclusion. In addition, estrogen has been recently approved in some countries as a preventative therapy for coronary heart disease, which indicates an increasing appreciation of its cardioprotective properties. Minimum daily dosages of estrogen to prevent bone loss and 10 treat mild 10 moderate menopausal symptom s are as follows: oral conjugated equine estrogens O.625mg, transdermal estradiol O.05mg, oral ethinyl estradiol O.02mg. estrone sulfate O.625mg and piperazine estrone O.75mg; subcUianeous implants of estradiol 50mg have a comparable efficacy. Low dosages of progeslogens, for example medroxyprogesterone acetate 2.5mg, levonorgestrel O.03mg, and norethisterone acetate O.25mg, can be administered concomitantly as contin uous or cyclic regimens, to prevent endometrial hyperplasia. Urogenital deficiency can also be effectively treated with oral and intravaginal estriol, or intravaginal estradiol, although the formulations available are unlike ly 10 achieve plasma concentrations of estrogen sufficient to pre vent menopausal bone loss. HRT is best initiated at the climactcric, before appreciable bone loss has occurred .
Limited comparative cost effectiveness data indicate that HRT is preferable to most other therapeutic options (e.g. veralipride, Chinese medicines) for the treatment of menopausal symptoms (Fuj ino el aL 1993; Ho n sberger et al. 1993; Tieffenberg et aL 1993a,b) . However, these short term prospeclive data require confirmation in long t erm therapy. Actual clinical data concerning the effects of osteoporotic fraclUre and menopausal symptoms on quality of life are also insuffici ent for a complete evaluation of cost utility (see Whittington & Faulds 1994) , a lthough evidence to date s uggests that effects may have been underestimated in pharmacoeconomic analyses.
Whereas the impetus for curative treatment comes from the patient, preventative measures are usually initiated by clinicians. The observation that 80% of prescri ptions for HRT are intended for alleviation of menopausal symptoms indicates that the curati ve rather than preventative features of HRT are currently the primary reason for prescription. Cost-utility data also reflect the economic significance of menopausal symptoms. However, sy mptoms have a limited duration , and in many women, alleviation of symptoms is a consideration only during the immediate perimenopausal period. Thus, relief from symptoms is not an incentive to continue wi th the long term therapy required to prevent osteoporotic fracture or cardiovascular disease. The long duration of therapy required for full benefit indicates that acceptability and tolerability of HRT are important considerations, as well as the safety profile regarding risk factors such as breast cancer (reviewed in Part II; Whittington & Faulds 1994).
Formulary Considerations
Formulary decisions concerning HRT for menopausal symptoms and urogenital deficiency should consider which patients would derive the most benPharmacoEconomics 5 (5) 1994 efit from HRT, the preferred dosage regimen and the reliability of the pharmacoeconomic evidence.
The majority of phannacoeconomic studies have suggested thai selective the rapy is more cost effect ive than universal treatment. From an economic perspective, women with severe menopausal symptoms are the most eligible candidates for HRT, as arc those with high risk of osteoporotic fracture or coronary hearl disease. In particular, treatment in women who have undergone hysterectomy is more cost effective than treatment in women with intact uteri. Preliminary data suggest that widespread use of HRT may also be applicable in women aged?: 65 years with urinary incontinence, but supporling evidence is r eq uired . Comparative pharmacoeconomic data are insuffi cient to make conclusions regarding dosage regimens. Preliminary evidence suggests that oral conjugated estrogens are more cost effecti ve than transdermal estradiol in preventing menopausal symptoms, but no l ong term data are available.
Thus, while many i ssues need to be resolved before the full pharmacocconomic benefits of HRT are recogni sed, there is little doubt that HRTis both medically and economically beneficial in women with severe menopausal symptoms . In women with mild to moderate symptoms, HRT is also economically justified if compliance is good. Added bene fi cial effects o n osteoporosis and card iovascular o utcomes (Whittingto n & Faulds 1994)2, balanced against the level of monitoring thai accompanies therapy, and the drug acquisition cost, will ultimately determine the degree of cost effectiveness.
